10. Emerald Health Therapeutics Inc. (TSX: EMH) $674 Million
Emerald Health Therapeutics, Inc. operates through Emerald Health Therapeutics Canada Inc. (“EHTC”), a wholly owned subsidiary and Licensed Producer under Canada’s Access to Cannabis for Medical Purposes Regulations. Through EHTC, Emerald is authorized to produce and sell dried cannabis and cannabis oil for medical purposes. It operates an indoor facility in Victoria, BC, and is building a 500,000 ft2 greenhouse on 32 acres in Metro Vancouver, with expansion potential to 1 million ft2 to serve the anticipated legal Canadian adult-use cannabis market starting in 2018. Emerald owns 50% of a Joint Venture with Village Farms International, Inc. that is converting an existing 1.1 million ft2greenhouse in Delta, BC to grow cannabis.
- Feb 14, 2018 Emerald Health Therapeutics Raises $18M
9. The Hydropothecary Corporation (TSX: THCX) $699 Million
The Hydropothecary Corporation is an authorized licensed producer and distributor of medical cannabis licensed by Health Canada under the Access to Cannabis for Medical Purposes Regulations (Canada). Hydropothecary creates award-winning innovative, easy to use and easy to understand products. Hydropothecary is rapidly increasing its production capacity in the lead-up to recreational adult-use cannabis. Expansion plans will result in a total of 1.3 million sq. ft. of production space, producing 108,000 kg of dried cannabis per year, making Hydropothecary one of the largest producers in the country.
8. CannTrust Holdings Inc. (TSX: TRST) $791 Million
As a federally regulated licensed producer, CannTrust™ brings more than 40 years of pharmacy and healthcare experience to the medical cannabis industry. CannTrust currently operates a 60,000 square foot state-of-the-art hydroponic facility in Vaughan, Ontario, as well as the recently completed 250,000 square foot Phase 1 redevelopment of its 430,000 square foot Niagara Greenhouse Facility. The Phase 2 expansion is underway and is anticipated to be completed and in cultivation towards the middle of 2018.
- Feb 12, 2018 CannTrust Holdings Receives Sales License for 250,000 sq. ft. Greenhouse Facility
- Feb 15, 2018 CannTrust Holdings Closes US$15 Million Mortgage for Cultivation Facility
- March 2, 2018 CannTrust Holding to Begin Trading on the Toronto Stock Exchange
7. CanniMed Therapeutics Inc. (TSX: CMED) $948 Million
CanniMed is a Canadian-based, international plant biopharmaceutical company and a leader in the Canadian medical cannabis industry, with 17 years of pharmaceutical cannabis cultivation experience, state-of-the-art, GMP-compliant production process and world class research and development platforms with a wide range of pharmaceutical-grade cannabis products. In addition, CanniMed has an active plant biotechnology research and product development program focused on the production of plant-based materials for pharmaceutical, agricultural and environmental applications.
- Feb 28, 2018 Aurora Cannabis Receives Regulatory Approval for CanniMed Acquisition
- Feb 28, 2018 CanniMed Releases New Product Line – CanniMed Topical Cream
6. MedReleaf Corp. (TSX: LEAF) $1.9 Billion
Voted Top Licensed Producer at the 2017 Lift Canadian Cannabis Awards, MedReleaf is an R&D-driven company dedicated to innovation, operational excellence and the production of top-quality cannabis. Sourced from around the world and carefully cultivated in one of two state-of-the-art ICH-GMP and ISO 9001 certified facilities in Ontario, the Company delivers a variety of premium products for the global medical market and is committed to serving the therapeutic needs of its medical patients and providing a compelling product assortment for the adult-use recreational consumer.
- Feb 7, 2018 MedReleaf (TSX: LEAF) Gains Approval From Health Canada To Sell Cannabis Oil Softgel Capsules
- Feb 13, 2018 MedReleaf (TSE: LEAF) Announces 3rd Quarter Financials, $11.4M in Sales
- Feb 26, 2018 MedReleaf Purchases 1M sq. ft. Greenhouse Cultivation Facility
5. Cronos Group Inc. (TSXV: MJN) (NASDAQ: CRON) $2 Billion
Cronos Group is a globally diversified and vertically integrated cannabis company with a presence across four continents. The Company operates two wholly-owned Canadian Licensed Producers regulated under Health Canada’s Access to Cannabis for Medical Purposes Regulations: Peace Naturals Project Inc. (Ontario) and Original BC Ltd. (British Columbia), which is based in the Okanagan Valley. The Company has multiple international production and distribution platforms including: Cronos Israel and Cronos Australia. Through an exclusive distribution agreement, Cronos Group has access to over 12,000 pharmacies in Germany.
- Feb 5, 2018 The Cronos Group Has Been Granted Licenses for Cultivation in Australia
- Feb 26, 2018 The Cronos Group Makes Move to the NASDAQ
4. Aphria Inc. (TSX: APH) $2.23 Billion
Aphria Inc., one of Canada’s lowest cost producers, produces, supplies and sells medical cannabis. Located in Leamington, Ontario, the greenhouse capital of Canada. Aphria is truly powered by sunlight, allowing for the most natural growing conditions available. Aphria is committed to providing pharma-grade medical cannabis, superior patient care while balancing patient economics and returns to shareholders.
- Jan 31, 2018 Canadian Company Aphria Purchases Nuuvera for $826M to Create International Powerhouse
- Feb 14, 2018 Aphria Signs LOI to Supply 12 Tons of Cannabis to Quebec a Year
3. GW Pharmaceuticals Plc (NASDAQ: GWPH) $2.93 Billion
Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. GW, along with its U.S. subsidiary Greenwich Biosciences, is advancing an orphan drug program in the field of childhood-onset epilepsy with a focus on Epidiolex (cannabidiol), for which GW has submitted regulatory applications in the U.S. and Europe for the adjunctive treatment of Lennox-Gastaut syndrome and Dravet syndrome. The Company continues to evaluate Epidiolex in additional rare epilepsy conditions and currently has ongoing clinical trials in Tuberous Sclerosis Complex and Infantile Spasms. GW commercialized the world’s first plant-derived cannabinoid prescription drug, Sativex® (nabiximols), which is approved for the treatment of spasticity due to multiple sclerosis in numerous countries outside the United States and for which the company is now planning a US Phase 3 trial.
- Feb 22, 2018 GW Pharma’s New Compound GWP42006 Fails Initial Trial Testing https://cashcroptoday.com/wp-admin/post.php?post=3226&action=edit
- Feb 22, 2018 GW Pharmaceuticals Receives Orphan Drug Designation from the European Medicines Agency (EMA)
2. Aurora Cannabis Inc. (TSX: ACB) $5.53 Billion
Aurora’s wholly-owned subsidiary, Aurora Cannabis Enterprises Inc., is a licensed producer of medical cannabis pursuant to Health Canada’s Access to Cannabis for Medical Purposes Regulations (“ACMPR”). The Company operates a 55,200 square foot, state-of-the-art production facility in Mountain View County, Alberta and a second 40,000 square foot high-technology production facility in Pointe-Claire, Quebec on Montreal’sWest Island. In January 2018, Aurora’s 800,000 square foot flagship cultivation facility, Aurora Sky is expected to produce over 100,000 kg per annum of cannabis. Aurora is completing a fourth facility in Lachute, Quebec utilizing its wholly owned subsidiary Aurora Larssen Projects Ltd.
- Feb 7, 2018- Aurora Cannabis (TSX: ACB) Announces Aurora Pro, B to B Services for the Cannabis Industry
- Feb 28, 2018 Aurora Cannabis Receives Regulatory Approval for CanniMed Acquisition
1. Canopy Growth Corporation (TSX: WEED) $6.23 Billion
Canopy Growth is a world-leading diversified cannabis and hemp company, offering distinct brands and curated cannabis varieties in dried, oil and Softgel capsule forms. Canopy Growth has established partnerships with leading sector names including cannabis icon Snoop Dogg, breeding legends DNA Genetics and Green House seeds, and Fortune 500 alcohol leader Constellation Brands, to name but a few. Canopy Growth operates seven cannabis production sites with over 665,000 square feet of production capacity, including over 500,000 square feet of GMP-certified production space. The Company has operations in seven countries across four continents.
